Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 1
2008 2
2009 1
2010 2
2011 2
2012 3
2013 6
2014 1
2015 3
2016 3
2017 3
2018 6
2019 9
2020 5
2021 8
2022 12
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody.
Nishiwaki N, Noma K, Ohara T, Kunitomo T, Kawasaki K, Akai M, Kobayashi T, Narusaka T, Kashima H, Sato H, Komoto S, Kato T, Maeda N, Kikuchi S, Tanabe S, Tazawa H, Shirakawa Y, Fujiwara T. Nishiwaki N, et al. Among authors: ohara t. Cancer Immunol Immunother. 2023 Jul;72(7):2029-2044. doi: 10.1007/s00262-023-03378-7. Epub 2023 Feb 10. Cancer Immunol Immunother. 2023. PMID: 36764954 Free PMC article.
PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
Kawasaki K, Noma K, Kato T, Ohara T, Tanabe S, Takeda Y, Matsumoto H, Nishimura S, Kunitomo T, Akai M, Kobayashi T, Nishiwaki N, Kashima H, Maeda N, Kikuchi S, Tazawa H, Shirakawa Y, Fujiwara T. Kawasaki K, et al. Among authors: ohara t. Cancer Immunol Immunother. 2023 Nov;72(11):3787-3802. doi: 10.1007/s00262-023-03531-2. Epub 2023 Sep 5. Cancer Immunol Immunother. 2023. PMID: 37668710 Free PMC article.
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y, Tazawa H, Yamada M, Kanaya N, Fushimi T, Kikuchi S, Kuroda S, Ohara T, Noma K, Yoshida R, Umeda Y, Urata Y, Kagawa S, Fujiwara T. Kajiwara Y, et al. Among authors: ohara t. Cancer Immunol Immunother. 2023 May;72(5):1285-1300. doi: 10.1007/s00262-022-03334-x. Epub 2022 Nov 27. Cancer Immunol Immunother. 2023. PMID: 36436021 Free article.
Design and biological activity of a novel fungicide, quinofumelin.
Ito H, Takada T, Morimoto M, Komai H, Kajino F, Ohara T, Tamagawa Y, Tsuda M, Banba S. Ito H, et al. Among authors: ohara t. J Pestic Sci. 2023 Feb 20;48(1):22-27. doi: 10.1584/jpestics.D22-042. J Pestic Sci. 2023. PMID: 36874637 Free PMC article.
Functional Blockage of S100A8/A9 Ameliorates Ischemia-Reperfusion Injury in the Lung.
Nakata K, Okazaki M, Sakaue T, Kinoshita R, Komoda Y, Shimizu D, Yamamoto H, Tanaka S, Suzawa K, Shien K, Miyoshi K, Yamamoto H, Ohara T, Sugimoto S, Yamane M, Matsukawa A, Sakaguchi M, Toyooka S. Nakata K, et al. Among authors: ohara t. Bioengineering (Basel). 2022 Nov 10;9(11):673. doi: 10.3390/bioengineering9110673. Bioengineering (Basel). 2022. PMID: 36354584 Free PMC article.
Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment.
Sato H, Noma K, Ohara T, Kawasaki K, Akai M, Kobayashi T, Nishiwaki N, Narusaka T, Komoto S, Kashima H, Katsura Y, Kato T, Kikuchi S, Tazawa H, Kagawa S, Shirakawa Y, Kobayashi H, Fujiwara T. Sato H, et al. Among authors: ohara t. Sci Rep. 2022 Nov 23;12(1):20152. doi: 10.1038/s41598-022-24313-3. Sci Rep. 2022. PMID: 36418422 Free PMC article.
78 results